Longeveron Gets US FDA Approval for Phase 2 Trial of Laromestrocel
MT Newswires Live
Jul 08
Longeveron (LGCN) said Tuesday the US Food and Drug Administration has cleared its investigational new drug application for stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy.
The company said it plans to begin phase 2 clinical trials in H1 2026. There are currently no approved therapies for pediatric dilated cardiomyopathy, the company said.
Laromestrocel is a proprietary investigational cellular therapy derived from mesenchymal stem cells that may lead to anti-inflammatory, pro-vascular regenerative responses, the company said.
Shares of Longeveron were up 7% in Tuesday morning trading.
Price: 1.38, Change: +0.09, Percent Change: +6.98
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.